Detalhe da pesquisa
1.
Efficacy of enfortumab vedotin in advanced urothelial cancer: Analysis from the Urothelial Cancer Network to Investigate Therapeutic Experiences (UNITE) study.
Cancer
; 128(6): 1194-1205, 2022 Mar 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-34882781
2.
Repeat Next-Generation Sequencing Testing on Progression in Men With Metastatic Prostate Cancer Can Identify New Actionable Alterations.
JCO Precis Oncol
; 8: e2300567, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38579192
3.
Somatic alterations of TP53 and MDM2 associated with response to enfortumab vedotin in patients with advanced urothelial cancer.
Front Oncol
; 13: 1161089, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37091148
4.
Treatment Rechallenge With Immune Checkpoint Inhibitors in Advanced Urothelial Carcinoma.
Clin Genitourin Cancer
; 21(2): 286-294, 2023 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36481176
5.
Impact of Squamous Histology on Clinical Outcomes and Molecular Profiling in Metastatic Urothelial Carcinoma Patients Treated With Immune Checkpoint Inhibitors or Enfortumab Vedotin.
Clin Genitourin Cancer
; 21(5): e394-e404, 2023 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37316414
6.
Response and Outcomes of Maintenance Avelumab After Platinum-Based Chemotherapy (PBC) in Patients With Advanced Urothelial Carcinoma (aUC): "Real World" Experience.
Clin Genitourin Cancer
; 21(5): 584-593, 2023 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37414620
7.
Repeat Treatment of Patients With Advanced Urothelial Carcinoma With Immune Checkpoint Inhibitors Following Prior Progression on a Checkpoint Inhibitor Regimen: A Case Series.
Clin Genitourin Cancer
; 20(2): 189-194, 2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-34998700
8.
APOBEC Mutational Signature and Tumor Mutational Burden as Predictors of Clinical Outcomes and Treatment Response in Patients With Advanced Urothelial Cancer.
Front Oncol
; 12: 816706, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35321431
9.
Association of the Time to Immune Checkpoint Inhibitor (ICI) Initiation and Outcomes With Second Line ICI in Patients With Advanced Urothelial Carcinoma.
Clin Genitourin Cancer
; 20(6): 558-567, 2022 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-36155169
10.
Central Nervous System Disease Progression Among Patients With Metastatic Urothelial Carcinoma Treated With Enfortumab Vedotin: A Case Series.
Clin Genitourin Cancer
; 22(2): 315-321, 2024 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-38114390